Owing to the increasing number of approvals of cell therapies, and a sharp rise in associated clinical trials, the demand for advanced cell therapy consumables is likely to witness significant surge, in the coming years
Roots Analysis has announced the addition of “Cell Therapy Media, Kits, Reagents and Surfaces Market, 2023-2035” report to its list of offerings.
In pursuit of both time and cost savings, as well as to mitigate the regulatory challenges associated with manufacturing of cell therapy consumables, around 90% of the cell therapy developers prefer to outsource culture media, kits, reagents and extracellular matrices to consumable providers, which claim to have the required expertise in order to yield high quality raw materials.
To order this 300+ page report, which features 160+ figures and 180+ tables, please visit this link
Presently, more than 80 players claim to offer cell therapy consumables
This segment of the industry is dominated by the presence of start-ups / small firms (2-51 employees) and mid-sized companies (51-500 employees), which collectively represent close to 75% of the total consumable providers. In addition, more than 55% of the firms are based in North America.
Cell therapy media products capture the highest share (57%) of the market
Most of the cell therapy media products are intended to be used for stem cell therapies (80%), followed by those being developed for T-cell therapies (15%). In addition, 59% of the media products are used for cell proliferation. Further, cell therapy kits capture around 26% of the consumables market.
More than 30 companies are engaged in offering cell therapy reagents and extracellular matrices
Majority of the cell therapy reagents are used for cell expansion (46%), followed by those intended for use in cell proliferation (38%). In addition, most of the cell therapy extracellular matrices are composed of laminin coating (32%), followed by those comprising of fibronectin (26%).
125 consumable facilities dedicated to cell therapies have been established, worldwide
North America has emerged as the manufacturing hub for cell therapy consumables, featuring the presence of nearly 55% of the facilities; this is followed by the facilities based in Europe (26%). Other emerging regions include (in decreasing order of number of facilities) China, Japan, South Korea and India.
Partnership activity in this domain has increased at a CAGR of over 40%, during 2015- 2022
Distribution agreements emerged as the most popular type of partnership model adopted by industry stakeholders (24%), followed by mergers and acquisitions (18%). Further, most of the deals were inked for cell therapy media related collaborations (65%).
Over 250 cell therapy developers are likely to forge strategic alliances with consumable providers
Around 15% of the cell therapy developers claim to have the required expertise to offer services for more than two unique types of cell therapies. Notable examples include (in alphabetical order) Aspire Health Science, Bio Elpida and The Discovery Labs Center for Breakthrough Medicines.
Global demand for cell therapy consumables is anticipated to grow at a CAGR of 14%, till 2035
The commercial demand for cell therapy consumables is projected to increase at a CAGR of 17.0%. Further, the clinical demand for cell therapy consumables is projected to increase at a CAGR of 8.1%.
North America and Asia-Pacific are anticipated to capture over 75% of the market share, in 2035
In terms of type of product, the current market is driven by cell therapy media (close to 70%); this trend is unlikely to change in the foreseen future. Based on type of cell therapy, majority of the revenue share (61%) of the overall market in 2035 is projected to be driven by T-cell therapies.
To request a sample copy / brochure of this report, please visit this link
The financial opportunity within the cell therapy media, kits, reagents and surfaces market has been analyzed across the following segments:
The report includes profiles of key players (listed below) engaged in offering media, kits, reagents and surfaces for cell therapies, across discovery, preclinical, clinical and commercial scales of operation; each profile features a brief overview of the company, along with details related to its cell therapy media, kits, reagents and extracellular matrices portfolio, recent developments, and an informed future outlook.
For additional details, please visit https://www.rootsanalysis.com/reports/cell-therapy-consumables-market.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
MEDIA CITATIONS
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES
.png)
